Shou-hong Wang

Dr. Shou-hong Wang

Guangdong Provincial People’s Hospital

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2021 in Frontiers in Nutrition
Verified
Journal Article
Open access
ZWZhong-Hua Wang
Zhong-Hua Wang
YLYing-Wen Lin
Ying-Wen Lin
XWXue-Biao Wei
Xue-Biao Wei
FLFei Li
Fei Li
XLXiao-Long Liao
Xiao-Long Liao
SWShou-hong Wang
Shou-hong Wang
Background: The prognostic nutritional index (PNI) has been described as a simple risk-stratified tool for several diseases. We explored the predictive role of the PNI on coronavirus disease 2019 (COVID-19) severity.Methods: A total of 101 patients with COVID-19 were included in this retrospective study from January 2020 to March 2020. They were divided into two groups according to COVID-19 severity: non-critical (n = 56) and critical (n = 45). The PNI was calculated upon hospital admission: 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (/mm3). Critical COVID-19 was defined as having one of the following features: respiratory failure necessitating mechanical ventilation; shock; organ dysfunction necessitating admission to the intensive care unit (ICU). The correlation between the PNI with COVID-19 severity was analyzed.Results: The PNI was significantly lower in critically ill than that in non-critically ill patients (P < 0.001). The receiver operating characteristic curve indicated that the PNI was a good discrimination factor for identifying COVID-19 severity (P < 0.001). Multivariate logistic regression analysis showed the PNI to be an independent risk factor for critical illness due to COVID-19 (P = 0.002).Conclusions: The PNI is a valuable biomarker that could be used to discriminate COVID-19 severity.

1 February 2020 in European Journal of Pharmacology
Verified
Journal Article
Closed access
XWXue-Biao Wei
Xue-Biao Wei
ZWZhong-Hua Wang
Zhong-Hua Wang
XLXiao-Long Liao
Xiao-Long Liao
WGWei-Xin Guo
Wei-Xin Guo
JWJian-Yi Wen
Jian-Yi Wen
SWShou-hong Wang
Shou-hong Wang

1 December 2020 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
XLXiao-Long Liao
Xiao-Long Liao
ZWZhong-Hua Wang
Zhong-Hua Wang
XLXiu-Na Liang
Xiu-Na Liang
JLJun Liang
Jun Liang
XWXue-Biao Wei
Xue-Biao Wei
WGWei-Xin Guo
Wei-Xin Guo
Purpose: The relationship between circulating selenium and diabetes mellitus (DM) remains inconsistent. Therefore, the relationship between circulating selenium and DM was investigated in the present study. Patients and Methods: All participants (aged ≥ 18 years) were included from the National Health and Nutrition Examination Survey (NHANES) 1999– 2006. Selenium concentrations from the fasting serum samples were determined using inductively coupled mass spectrometry, then grouped into quartiles. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by using multivariate logistic regression analysis and the results were stratified by age and sex. Results: A total of 2,903 (61.9± 13.7 years old) participants (49.3% males) were enrolled, and 580 (19.97%) of them had DM. The mean levels of selenium were 136.4± 19.6 μg/L. Patients with DM (138.76± 20.02 vs 135.88± 19.44, P=0.002) had higher selenium levels compared to those without DM. The OR for DM was 1.12 (95% CI=1.01– 1.24; P=0.0270) for each 10 μg/L increment in selenium, and subjects in the highest quartile of selenium levels (> 147.00 uμg/L) had 2.82 (95% CI=1.55– 5.11; P=0.0007) times higher risk of DM compared to the lowest quartile of selenium levels. Subgroup analysis showed that selenium was independently associated with DM only in female aged < 65 years. Conclusion: Circulating selenium levels were positively associated with the odds of DM, but difference in sex and age.

31 January 2022 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
ZWZhong‐Hua Wang
Zhong‐Hua Wang
BFBing‐Qi Fu
Bing‐Qi Fu
YLYing‐Wen Lin
Ying‐Wen Lin
XWXue‐Biao Wei
Xue‐Biao Wei
HGHeng Geng
Heng Geng
SWShou-hong Wang
Shou-hong Wang
Red blood cell distribution width (RDW) was frequently assessed in COVID‐19 infection and reported to be associated with adverse outcomes. However, there was no consensus regarding the optimal cutoff value for RDW. Records of 98 patients with COVID‐19 from the First People's Hospital of Jingzhou were reviewed. They were divided into two groups according to the cutoff value for RDW on admission by receiver operator characteristic curve analysis: ≤11.5% (n = 50) and >11.5% (n = 48). The association of RDW with the severity and outcomes of COVID‐19 was analyzed. The receiver operating characteristic curve indicated that the RDW was a good discrimination factor for identifying COVID‐19 severity (area under the curve = 0.728, 95% CI: 0.626–0.830, p < 0.001). Patients with RDW > 11.5% more frequently suffered from critical COVID‐19 than those with RDW ≤ 11.5% (62.5% vs. 26.0%, p < 0.001). Multivariate logistic regression analysis showed RDW to be an independent predictor for critical illness due to COVID‐19 (OR = 2.40, 95% CI: 1.27−4.55, p = 0.007). A similar result was obtained when we included RDW > 11.5% into another model instead of RDW as a continuous variable (OR = 5.41, 95% CI: 1.53−19.10, p = 0.009). RDW, as an inexpensive and routinely measured parameter, showed promise as a predictor for critical illness in patients with COVID‐19 infection. RDW > 11.5% could be the optimal cutoff to discriminate critical COVID‐19 infection.

29 January 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
XWXue-biao Wei
Xue-biao Wei
ZWZhong-Hua Wang
Zhong-Hua Wang
XLXiao-Long Liao
Xiao-Long Liao
WGWei-Xin Guo
Wei-Xin Guo
TQTiehe Qin
Tiehe Qin
SWShou-hong Wang
Shou-hong Wang
Background: The therapeutic role of neuromuscular blocking agents (NMBA) in patients with acute respiratory distress syndrome (ARDS) remains controversial. Methods: We systematically reviewed randomized controlled trials investigating the use of NMBA in ARDS patients from inception to July 2019. Relative risk (RR) was calculated for the incidence of barotrauma and mortality using the random-effect or fixed-effect model according to heterogeneity analysis. Results: Data were combined from five randomized controlled trials that included 1,461 patients (724 in the NMBA group and 737 in the control group). Pooled analysis showed that NMBA infusion did not reduce 28-day mortality (RR = 0.72, 95% confidence interval (CI) 0.44 to 1.17, P=0.180, I-squared = 62.8%), but was associated with lower intensive care unit (ICU) mortality (RR = 0.60, 95% CI 0.41 to 0.88, P = 0.009, I-squared = 9.2%). In addition, the incidence of barotrauma was significantly lower in patients treated with NMBA (RR = 0.53, 95% CI 0.33 to 0.84, P = 0.007, I-squared = 0). However, infusion of NMBA might increase the risk of ICU-acquired weakness (RR = 1.34, 95% CI 0.97 to 1.84, P = 0.066, I-squared = 0). Conclusion: Infusion of NMBA could reduce ICU mortality and the incidence of barotrauma. The risk of ICU-acquired weakness was higher in moderate-to-severe ARDS patients treated with NMBA. The real effects of NMBA need to be further evaluated and confirmed by a study with a stricter design.

15 November 2023 in Journal of Cardiovascular Translational Research
Verified
Journal Article
Closed access
PDF file
XWXue-biao Wei
Xue-biao Wei
PRPeng Ran
Peng Ran
YNYuxin Nong
Yuxin Nong
TYTao Ye
Tao Ye
XJXuhua Jian
Xuhua Jian
JCJiyan Chen
Jiyan Chen